- Home
- BIIB vs TTWO Comparison
BIIB vs TTWO Comparison
Compare BIIB & TTWO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- TTWO
- Stock Information
- Founded
- BIIB 1978
- TTWO 1993
- Country
- BIIB United States
- TTWO United States
- Employees
- BIIB N/A
- TTWO N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- TTWO Computer Software: Prepackaged Software
- Sector
- BIIB Health Care
- TTWO Technology
- Exchange
- BIIB Nasdaq
- TTWO Nasdaq
- Market Cap
- BIIB 18.7B
- TTWO 43.0B
- IPO Year
- BIIB 1991
- TTWO 1997
- Fundamental
- Price
- BIIB $144.86
- TTWO $246.26
- Analyst Decision
- BIIB Buy
- TTWO Strong Buy
- Analyst Count
- BIIB 27
- TTWO 21
- Target Price
- BIIB $188.09
- TTWO $248.19
- AVG Volume (30 Days)
- BIIB 1.5M
- TTWO 1.3M
- Earning Date
- BIIB 10-29-2025
- TTWO 11-05-2025
- Dividend Yield
- BIIB N/A
- TTWO N/A
- EPS Growth
- BIIB 31.67
- TTWO N/A
- EPS
- BIIB 10.45
- TTWO N/A
- Revenue
- BIIB $9,997,000,000.00
- TTWO $5,799,200,000.00
- Revenue This Year
- BIIB $2.00
- TTWO $11.46
- Revenue Next Year
- BIIB N/A
- TTWO $52.38
- P/E Ratio
- BIIB $13.86
- TTWO N/A
- Revenue Growth
- BIIB 3.36
- TTWO 7.33
- 52 Week Low
- BIIB $110.04
- TTWO $146.76
- 52 Week High
- BIIB $204.18
- TTWO $250.45
- Technical
- Relative Strength Index (RSI)
- BIIB 60.92
- TTWO 63.19
- Support Level
- BIIB $139.54
- TTWO $243.46
- Resistance Level
- BIIB $143.74
- TTWO $250.45
- Average True Range (ATR)
- BIIB 4.32
- TTWO 4.97
- MACD
- BIIB 0.69
- TTWO 1.22
- Stochastic Oscillator
- BIIB 71.89
- TTWO 80.91
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About TTWO Take-Two Interactive Software Inc.
Take-Two is one of the largest global developers and publishers of video games, with labels including Rockstar, 2K, and Zynga. Grand Theft Auto is the firm's biggest franchise, accounting for about 30% of total sales for the past decade. NBA 2K is the industry's dominant basketball video game, with Take-Two releasing a new version annually. Other notable franchises include Red Dead Redemption, Borderlands, and Civilization. Typically, more than three quarters of the firm's sales are from in-game spending, with the remainder coming from initial game sales. Since acquiring Zynga in 2022, mobile makes up about half of total sales.